Article Text

Download PDFPDF

SAT0614 New variant in the il1rn-gene associated with late onset and atypical presentation of dira
  1. J.B. Kuemmerle-Deschner1,
  2. K. Hoertnagel2,
  3. S. Schlipf3,
  4. S. Hansmann4,
  5. A. Hospach5,
  6. X. Liu6,
  7. S.M. Benseler7,
  8. A.N. Weber6
  1. 1Department of Pediatrics, Division of Rheumatology, University Hospital Tuebingen
  2. 2Praxis für Humangenetik Tübingen, Tuebingen
  3. 3Kinderarztpraxis Dr. Lakner, Schwäbisch Gmünd
  4. 4Department of Pediatrics, Division of Pediatric Rheumatology, UNIVERSITY HOSPITAL TUEBINGEN, Tuebingen
  5. 5Zentrum für Pädiatrische Rheumatologie, Klinikum Stuttgart, Olgahospital, Stuttgart
  6. 6Department of Immunology, University of Tübingen, Tübingen, Germany
  7. 7Rheumatology, Department of Paediatrics, Alberta Children’s Hospital, University of Calgary, Alberta, Calgary, Alberta, Canada


Background Deficiency of the interleukin-1 receptor antagonist (DIRA) is an autoinflammatory disease characterised by severe systemic inflammation with bone and skin involvement present in the first days of life.

Objectives We report a novel variant in the IL1RN-gene associated an atypical phenotype of DIRA.

Methods A 3 year-old Caucasian boy presented with recurrent monthly episodes of fever and fatigue, associated with lymphadenopathy, pericarditis, pleuritis, pancreatitis, and arthritis involving sacroiliac, hip, knee and ankle joints in the absence of any skin involvement. Symptoms had started at age one and had progressed over time to life-threatening episodes requiring intensive care therapy. Throughout, inflammatory parameters including ESR, CRP, SAA, S100A8/9, leukocytes, and platelets were highly elevated. Treatment with colchicine and steroids improved symptoms, however did not prevent flares. Immune deficiencies were ruled out; genetic testing for FMF, CAPS, TRAPS, HIDS and DITRA did not reveal variants in the associated genes.

Results Whole exome sequencing detected a novel homozygous stop variant c.62C>G; p.Ser21* in the ILRN gene (NM_173842.2). Mother, father and brother are heterozygous for the same variant. In addition, three variants of unknown significance were identified in the patient‘s PCGF5, CPA1 and SPTA1 genes. Functional studies revealed only marginal secretion of IL-1RA in the patient’s unstimulated leucocytes and after stimulation with IL-1β and LPS, confirming the disease-causing nature of the variant. Subsequently, IL-1 inhibition with anakinra at 2 mg/kg/d was started resulting in complete resolution of clinical symptoms, normal inflammatory markers and dramatically improved energy levels. Intolerance to daily subcutaneous injections prompted a switch to canakinumab at 4 mg/kg/4 weeks. However patient’s and mothers assessment of disease activity was inferior on canakinumab compared to anakinra. After four months a flare appeared and lead to return to anakinra.

Conclusions This is the first report of the novel c.62C>G; p.Ser21* variant in the IL1RN-gene primarily causing severe serositis in a homozygous carrier, while heterozygous family members were completely symptom free. Skin disease, one of the most prominent features in other patients with DIRA was not observed in this patient, while Il-1 inhibition was likewise effective.

Pathogenic variants in all reported DIRA patients so far affect all 4 isoforms of IL-1RA.1 The different phenotype in the patient reported here, may be due to the selective loss of secreted IL1RN.

Reference [1] Aksentijevich, et al. N Engl J Med2009;360:2426–2437.

Disclosure of Interest J. Kuemmerle-Deschner Grant/research support from: Novartis, SOBI, Consultant for: Novartis, SOBI, K. Hoertnagel: None declared, S. Schlipf: None declared, S. Hansmann: None declared, A. Hospach: None declared, X. Liu: None declared, S. Benseler: None declared, A. Weber: None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.